OncLive Highlights TOBY’s AI-Driven Urine VOC Approach for Prostate Cancer Detection

OncLive recently featured Dr. Thomas J. Polascik of Duke Cancer Institute discussing findings from a study of TOBY’s AI-based urine volatile organic compound (VOC) assay for prostate cancer detection.

The study explored the ability of urinary VOC analysis to detect prostate cancer in men with MRI-invisible lesions and in patients with low PSA values, highlighting the potential for complementary biomarker strategies in prostate cancer evaluation and risk stratification.

Watch the interview: Link

To learn more, visit Toby.health.

About TOBY, Inc.:
TOBY, inspired by Sherlock Holmes's Bloodhound, is a BioTech startup focused on the early detection of cancer utilizing mass spectrometry and Artificial Intelligence. TOBY has developed a single urine test that detects 10 cancers, representing over 60% of all new cases globally. This test identifies the unique molecular signature of cancer by combining the precision of mass spectrometry, changes in biomarkers (VOCs), and cutting-edge computational algorithms to deliver early, easy, and affordable cancer screening.

SOURCE TOBY, Inc.

Media Contact: [email protected]

Investor Contact: [email protected]